FindMyRecallSubscribe
Class II: temporary or reversible health riskTerminated

Lupin Pharmaceuticals Levonorgestrel and Ethinyl Estradiol Tablets Recall

Levonorgestrel and Ethinyl Estradiol Tablets USP, 0

Lupin Pharmaceuticals Inc. · Baltimore, MD

Risk level
Class II
Reported by FDA
Mar 18, 2020
Recall ID
D-1056-2020
Check your lot numberHow we source this data

Summary

Lupin Pharmaceuticals recalled Levonorgestrel and Ethinyl Estradiol Tablets starting Mar 9, 2020. The FDA classified it as Class II (temporary or reversible health risk) and published enforcement report D-1056-2020 on Mar 18, 2020. Reason: Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity. Status: Terminated.

Why it was recalled

Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity.

Product description

Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.05mg/0.03 mg, 0.075mg/0.04mg, and 0.125mg/0.03mg, packaged in 1 Wallet of 28 Tablets (NDC 68180-857-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-857-13); Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.

Lot numbers, UPCs & expiration codes

Lot #: L800951, Exp July 2020

Where it was sold

Nationwide in the USA and Puerto Rico.

What to do if you have this product

  • Compare the lot number and expiration date on your package with the codes above.
  • Don't stop taking a prescription medicine on your own. Call your pharmacist or doctor; they can confirm whether your supply is affected and arrange a replacement.
  • If you have symptoms you think are related, contact your doctor. In an emergency call 911.
  • Report side effects to FDA MedWatch at 1-800-FDA-1088.

Recall details

Recall number
D-1056-2020
Classification
Class II
Status
Terminated
Recall initiated
Mar 9, 2020
FDA report date
Mar 18, 2020
Quantity
9,897 cartons
Recall type
Voluntary: Firm initiated
Recalling firm
Lupin Pharmaceuticals Inc.

Original FDA data

Every field from FDA enforcement report D-1056-2020, exactly as published.

Show all FDA fields
City
Baltimore
State
MD
Status
Terminated
Country
United States
Event ID
85169
Address
Harborplace Tower
Address (line 2)
111 S Calvert St Fl 21st
Code information
Lot #: L800951, Exp July 2020
Postal code
21202-6174
Report date
Mar 18, 2020
Product type
Drugs
Recall number
D-1056-2020
Classification
Class II
Recalling firm
Lupin Pharmaceuticals Inc.
Product quantity
9,897 cartons
Termination date
May 25, 2021
Reason for recall
Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity.
Voluntary / mandated
Voluntary: Firm initiated
Product description
Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.05mg/0.03 mg, 0.075mg/0.04mg, and 0.125mg/0.03mg, packaged in 1 Wallet of 28 Tablets (NDC 68180-857-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-857-13); Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.
Distribution pattern
Nationwide in the USA and Puerto Rico.
Recall initiation date
Mar 9, 2020
Initial firm notification
Letter
Center classification date
Mar 24, 2020

How we source this data

Source: U.S. Food and Drug Administration enforcement report D-1056-2020, published Mar 18, 2020. View the source record (openFDA) · FDA enforcement reports

Last checked against FDA data: . Content last changed: .

FindMyRecall is an independent service and is not affiliated with or endorsed by the FDA. This page simplifies the official record; the FDA or manufacturer notice is authoritative, so follow its instructions. Medication information here is not individualized medical advice.

How we source and update recall data · Report incorrect information

Other recent drug recalls